News
-
-
PRESS RELEASE
Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit
Adolore BioTherapeutics to present innovative opioid-free chronic pain treatments at the 18th Annual Pain Therapeutics Summit in Boston, Ma, based on cutting-edge CA8* analgesic peptides & rdHSV vectors technology -
-
-
-
PRESS RELEASE
Adolore BioTherapeutics Announces Publication of Compelling Preclinical Efficacy and Safety Data Supporting Adolore's Non-opioid Analgesic Gene Therapy, ADLR-1001, For Treatment of Moderate to Severe Chronic Knee Pain Due to Osteoarthritis (OA)
Adolore BioTherapeutics validates a non-opioid analgesic gene therapy for chronic pain via local delivery to sensory neurons. Preclinical study supports opioid-free treatment for chronic knee pain due to OA -
-
PRESS RELEASE
Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference
Adolore BioTherapeutics to present at Virtual Investor Pitch Conference on June 17, 2024, 10:00 AM ET. CEO Roelof Rongen to provide an elevator pitch on breakthrough opioid-free gene therapy treatments for chronic pain -
-
PRESS RELEASE
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain
Adolore BioTherapeutics outlines pipeline development progress and business outlook focused on breakthrough gene therapy treatments for chronic pain, funded by NIH grant
